Antimalarial compositions and uses thereof

Patent metadata

Field	Value
Publication number	US-10947176-B2
Application number	US-201716311869-A
Country	US
Kind code	B2
Filing date	Jun 19, 2017
Priority date	Jun 20, 2016
Publication date	Mar 16, 2021
Grant date	Mar 16, 2021

Abstract

Provided herein are compounds, compositions and method of using thereof to treat or prevent malaria.

First claim

What is claimed is:

1. A pharmaceutical composition comprising:
(i) a vegetable oil; and
(ii) a compound of Formula (III) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:

wherein:
R 11 is a C 1 -C 6 alkyl moiety.

2. The pharmaceutical composition of claim 1 , wherein R 11 is C 6 alkyl.

3. The pharmaceutical composition of claim 1 , wherein the compound of Formula (III) is

4. The pharmaceutical composition of claim 1 , wherein the vegetable oil is selected from corn oil, peanut oil, sesame oil, olive oil, palm oil, safflower oil, soybean oil, cottonseed oil, rapeseed oil, sunflower oil and mixtures thereof.

5. The pharmaceutical composition of claim 4 , wherein the vegetable oil is sesame oil.

6. The pharmaceutical composition of claim 1 , wherein the concentration of the compound of Formula (III) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is greater than about 50 mg/mL.

7. The pharmaceutical composition of claim 1 , wherein the concentration of the compound of Formula (III) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is greater than about 100 mg/mL or greater than about 200 mg/mL.

8. A method for the treatment of malaria in a subject comprising administering to the subject a pharmaceutical composition of claim 1 .

9. The method of claim 8 , wherein the pharmaceutical composition is administered by subcutaneous or intramuscular injection.

10. The method of claim 8 , wherein the pharmaceutical composition is effective for sustained or controlled release.

11. The method of claim 8 , wherein the compound of Formula (III) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is administered at a dose of about 5 to about 20 mg/day.

12. The method of claim 8 , further comprising administering an additional antimalarial agent.

13. The method of claim 12 , wherein the additional antimalarial agent is selected from artemisinin, artemisinin derivatives, atovaquone, proguanil, quinine, chloroquine, amodiaquine, pyrimethamine, doxycycline, clindamycin, mefloquine, primaquine, pyronaridine, halofantrine, or ELQ-300.

14. The pharmaceutical composition of claim 1 , wherein the concentration of the compound of Formula (III) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is between about 20 mg/ml and about 300 mg/ml.

15. The pharmaceutical composition of claim 1 , further comprising surfactants, solubilizers, emulsifiers, preservatives, isotonicity agents, dispersing agents, wetting agents, fillers, solvents, buffers, stabilizers, lubricants, thickening agents, suspending agents, and any combinations thereof.

16. The method of claim 8 , wherein the compound of Formula (III) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is released from the pharmaceutical composition over a period of a minimum of about 30 days after administration.

17. The method of claim 8 , wherein the compound of Formula (III) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is released from the pharmaceutical composition at a rate providing an average concentration of trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione in the blood plasma of said subject of at least about 200 nM over about 13 weeks.

18. The method of claim 8 , wherein the compound of Formula (III) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is released from the pharmaceutical composition at a rate providing an average concentration of trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione in the blood plasma of said subject of at least 1000 nM, over about 13 weeks.

19. A pharmaceutical composition comprising:
(i) a biocompatible oil; and
(ii) a compound of Formula (III) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:

wherein:
R 11 is a C 1 -C 6 alkyl moiety.

20. The pharmaceutical composition of claim 19 , wherein R 11 is C 6 alkyl.

21. The pharmaceutical composition of claim 19 , wherein the biocompatible oil is castor oil, mineral oil, a vegetable oil, or a semi-synthetic vegetable oil.

22. A method for the treatment of malaria in a subject comprising administering to the subject a pharmaceutical composition of claim 19 .

Assignees

• Scripps Research Inst

Inventors

• Andahazy Wil Joseph
• Chatterjee Arnab K
• Mcnamara Case W
• Beasley Federico C
• Eliasen Anders Mikal
• Petrassi Hank Michael James
• Roland Jason T
• Wells Timothy
• Zatolochnaya Olga Vladimirovna
• Zhou Fei
• Schultz Peter G
• Gupta Anil Kumar

Classifications

• A61P33/06

  Antimalarials · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/222

  with compounds having aromatic groups, e.g. dipivefrine, ibopamine · CPC title

• A61K9/10 Primary

  Dispersions; Emulsions · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title